Key Stats for CL Stock
- Past week’s performance: (1.2%)
- 52-week range: $75 to $99
- Valuation model target price: $107
- Implied upside: 18.0% over 2.3 years
See how pricing and volume assumptions shape Colgate-Palmolive’s valuation using TIKR’s new Valuation Model (It’s free) >>>
Pricing Power Meets a Volume Problem
Colgate-Palmolive (CL) shares were little changed to modestly lower this week, extending a quiet stretch since the company reported second quarter results in late July. The stock trades well below its 52-week high, and this week’s move reflects lingering questions about whether recent earnings strength can hold once pricing gains fade.
Adjusted earnings per share came in at $0.99, above the $0.95 consensus estimate, while net sales rose 4.9% to $5.36 billion. But organic sales growth of just 2.4% was driven almost entirely by pricing, since volumes actually declined 0.4% companywide. North America was the weak spot, with organic sales falling 3% because volumes there dropped 3.9%, a trend CEO Noel Wallace called “not satisfactory” on the earnings call, citing slower category growth, market share losses, and retailer inventory reductions.
Gross margin still expanded 140 basis points to 61.5%, supported by cost initiatives and favorable product mix, and the company raised its full-year adjusted earnings per share guidance despite the domestic softness. Four of five global divisions posted organic sales growth outside North America, so the international business is doing much of the heavy lifting right now.
Because shipments fell 3% while consumption fell only about 1%, retailers appear to be working down inventory faster than actual demand is slowing. If Colgate-Palmolive stock stabilizes from here, that inventory gap closing is probably the first sign to watch for.
Model Colgate-Palmolive’s next five years with TIKR’s Guided Valuation Model (It’s free) >>>
Is CL Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 3.9%
- Operating margins: 21.4%
- Exit P/E multiple: 22.5x
Based on these inputs, the model estimates a target price of $107, implying 18.0% total upside from the current share price and a 7.3% annualized return over the next 2.3 years.
That return sits in the moderately attractive range, but not far above it, which fits a company where pricing is doing most of the growth work while volumes stay flat or negative. Because the exit multiple assumption matches Colgate-Palmolive’s own trailing multiple almost exactly, this model is not pricing in any re-rating, just steady execution.
The 21.4% operating margin assumption is close to the company’s five-year average, so further margin expansion beyond cost savings already in guidance would be the clearest path to upside surprise. Conversely, if North America volumes keep sliding, pricing alone may not be enough to sustain even the modest 3.9% revenue growth baked into the model.
Colgate-Palmolive’s toothpaste category leadership remains a genuine moat, even amid the volume softness domestically.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Household Products Rivals: How Colgate-Palmolive Compares
Procter & Gamble (PG) is Colgate-Palmolive’s largest and most direct competitor across oral care, personal care, and household categories. Procter & Gamble has generally posted steadier North American volumes than Colgate-Palmolive in recent quarters, and its scale gives it more leverage in retailer negotiations, though its overall organic growth has also leaned on pricing amid similar consumer value-seeking behavior across the category.
Unilever (UL) competes with Colgate-Palmolive primarily in personal care and home care, and has been undergoing its own portfolio simplification following calls from investors questioning the value of running a sprawling consumer conglomerate. Unilever’s oral care exposure is smaller than Colgate-Palmolive’s, giving Colgate-Palmolive a structural advantage in the category where it holds global market share leadership.
Colgate-Palmolive’s moat remains its toothpaste dominance worldwide, a position built over decades that is difficult for either rival to meaningfully erode, even as both fight for share in the broader household products aisle.
What’s Driving CL Stock Going Forward?
The India leadership change announced August 21 is a catalyst worth tracking. Kenvue veteran Manish Anandani takes over as managing director and chief executive of Colgate-Palmolive India effective September 28, succeeding an executive moving to a broader Asia Pacific role, a signal that the company is doubling down on one of its key long-term growth markets.
Investors will also watch for signs that North America volumes are stabilizing heading into the next earnings report. Management’s commentary about retailer inventory reductions suggests the destocking trend could ease in coming quarters if consumption trends hold steady, which would remove one of the biggest overhangs on the stock.
CEO Noel Wallace’s sale of 322,042 shares in early August, worth roughly $29.8 million, was a routine transaction tied to vested equity, but its size may keep drawing analyst questions about near-term confidence even as guidance moves higher.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Colgate-Palmolive?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CL, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CL alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze CL stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
